Non-Muscle Invasive Bladder Cancer Market

How big is Non-Muscle Invasive Bladder Cancer Market in 2026?

USD 5.2 billion in 2026 and USD 10.9 billion by 2036 at a 7.7% CAGR.

Global revenues of non-muscle invasive bladder cancer market are set to reach USD 5.2 billion in 2026. Non-muscle invasive bladder cancer covers urothelial tumors classified around Ta, T1 and carcinoma in situ, without invasion into the bladder muscle. The European Association of Urology 2026 guideline overview sets this scope and separates it from muscle-invasive and upper-tract disease. The National Cancer Institute describes transurethral tumor resection as the usual first treatment for early-stage disease, followed by intravesical therapy and cystoscopic surveillance. This creates a market that combines procedure-led care with recurring medicines, delivery systems and follow-up.

The clinical pathway changes with disease risk and response. The NCI stage-based treatment summary identifies mitomycin, gemcitabine and BCG as intravesical options after surgery. For patients with BCG-unresponsive high-risk disease and carcinoma in situ, the FDA lists pembrolizumab, nadofaragene firadenovec and nogapendekin alfa inbakicept-pmln among bladder-preserving options when cystectomy is not used. The category therefore extends across immunotherapy, chemotherapy, gene therapy and local delivery.

The FDA approved gemcitabine intravesical system in September 2025 and mitomycin intravesical solution in June 2025. In May 2026, it approved durvalumab with BCG for BCG-naive, high-risk NMIBC. These decisions enlarge the set of treatment and delivery choices that hospitals, urology practices and pharmacies must evaluate.

Key Takeaways

• The market is projected to reach USD 10.9 billion by 2036 from USD 5.2 billion in 2026, reflecting a 7.7% CAGR.
• Intravesical Immunotherapy leads the profiled treatment mix with a 39.0% share in 2026.
• Ta Stage accounts for 43.0% of disease-stage demand in 2026, ahead of T1 and CIS pathways in the defined taxonomy.
• Hospitals represent 47.0% of end-user demand in 2026, making procedure capacity and follow-up infrastructure central to adoption.
• Recurrence, BCG-unresponsive disease, repeated cystoscopy or resection and delayed cystectomy risk remain central constraints when treatment pathways are evaluated.
• Merck & Co., Inc., Johnson & Johnson, Pfizer Inc., Ferring Pharmaceuticals, CG Oncology, Bristol Myers Squibb, UroGen Pharma Ltd., AstraZeneca PLC, Roche Holding AG and Sesen Bio.

Analyst Perspective

"The market is shifting from a single BCG-centered pathway toward a portfolio of risk-specific and bladder-preserving options. Local delivery, durable response and repeatable follow-up will shape adoption as hospitals compare approved therapies with late-stage programs."

- Anurag Sharma, Principal Consultant at Future Market Insights

How is the Non-Muscle Invasive Bladder Cancer Market segmented?

The Non-Muscle Invasive Bladder Cancer industry is segmented by treatment type, disease stage, end user, distribution channel, therapy class and region.

By treatment type, the market includes Intravesical Immunotherapy, covering BCG Therapy and Novel Immunotherapies; Intravesical Chemotherapy, covering Mitomycin C and Gemcitabine; Surgical Treatment, covering Transurethral Resection of Bladder Tumor and Re-TURBT; and Others, covering Targeted Therapy and Combination Therapy. By disease stage, the market includes Ta Stage, covering Low-Grade Ta and High-Grade Ta; T1 Stage, covering Primary T1 and Recurrent T1; and Carcinoma in Situ, covering Primary CIS and Concurrent CIS. By end user, the market includes Hospitals, covering Cancer Hospitals and General Hospitals; Specialty Cancer Centers, covering Urology Clinics and Oncology Centers; Ambulatory Surgical Centers, covering Outpatient Surgery Centers and Day Care Centers; and Others, covering Research Institutes and Academic Medical Centers. By distribution channel, the market includes Hospital Pharmacies, covering Inpatient Pharmacies and Outpatient Pharmacies; Retail Pharmacies, covering Chain Pharmacies and Independent Pharmacies; Specialty Pharmacies, covering Oncology Pharmacies and Biologic Drug Providers; and Others, covering Government Procurement and Online Pharmacies. By therapy class, the market includes Immunotherapy, covering BCG-Based Therapy and Checkpoint Inhibitors; Chemotherapy, covering Intravesical Chemotherapy and Systemic Chemotherapy; Targeted Therapy, covering FGFR Inhibitors and Antibody-Based Therapy; and Others, covering Gene Therapy and Oncolytic Viral Therapy.

Why does Ta Stage lead demand within the disease stage category?

Ta Stage leads because these tumors remain in the innermost bladder lining and account for a broad set of low-grade and high-grade care decisions. The EAU staging overview defines NMIBC around Ta, T1 and CIS, while the National Cancer Institute separates low-, intermediate- and high-risk disease when describing treatment and surveillance.

• Ta Stage is projected to account for 43.0% share in 2026, reflecting the breadth of Ta pathways across low-grade and high-grade disease.
• Ta Stage includes Low-Grade Ta and High-Grade Ta. The grade, size, number of tumors and recurrence history influence the treatment intensity and follow-up required within this stage.
• T1 Stage includes Primary T1 and Recurrent T1. T1 disease has extended into connective tissue beneath the lining, so treatment selection requires closer risk assessment and progression monitoring.
• Carcinoma in Situ (CIS) includes Primary CIS and Concurrent CIS. CIS is a high-grade flat lesion that can occur alone or alongside papillary tumors, making accurate staging and response assessment important.

Why does Intravesical Immunotherapy lead demand within the treatment type category?

Intravesical immunotherapy leads because BCG remains a central treatment for higher-risk NMIBC after tumor resection, and newer immunotherapy combinations are extending the development pathway. The NCI treatment overview identifies BCG as a standard intravesical option, while the FDA's Anktiva approval demonstrates how an immune-stimulating agent can be paired with BCG in BCG-unresponsive CIS.

• Intravesical Immunotherapy is estimated to hold 39.0% share in 2026 because BCG-based care remains an anchor and newer combinations widen the treatment set.
• Intravesical Chemotherapy includes Mitomycin C and Gemcitabine. These agents are administered locally after resection or through newer sustained-release systems, with the NCI identifying both as intravesical treatment options.
• Surgical Treatment includes Transurethral Resection of Bladder Tumor (TURBT) and Re-TURBT. Repeat resection can be required when the initial procedure does not remove enough tumor or lacks an adequate muscle sample.
• Others includes Targeted Therapy and Combination Therapy. This branch captures treatment designs that combine mechanisms or focus on molecular features beyond the main intravesical immunotherapy, chemotherapy and surgical categories.

Why do Hospitals lead demand within the end user category?

Hospitals lead because they can connect TURBT or Re-TURBT, pathology, intravesical administration, cystoscopic surveillance and specialist escalation within one care network. The EAU guideline framework places diagnosis, risk classification, disease management and follow-up in a linked pathway, which favors settings with urology and oncology infrastructure.

• Hospitals hold a 47.0% share in 2026 because hospitals provide the procedure, treatment and monitoring infrastructure required by risk-stratified care.
• Specialty Cancer Centers include Urology Clinics and Oncology Centers. These settings concentrate disease-specific expertise, intravesical administration and clinical trial access.
• Ambulatory Surgical Centers include Outpatient Surgery Centers and Day Care Centers. They can support procedure-led treatment when patients do not require a full hospital stay.
• Others includes Research Institutes and Academic Medical Centers. These organizations support clinical research, translational work, training and evidence generation alongside patient care.

Why do Hospital Pharmacies lead demand within the distribution channel category?

Hospital Pharmacies lead because many NMIBC medicines are supplied into a supervised pathway that includes catheter-based instillation, treatment preparation, dosing controls and observation. The FDA label for Inlexzo describes a product inserted into the bladder with a co-packaged urinary catheter and scheduled removal, underscoring the role of institution-led distribution.

• Hospital Pharmacies account for 48.0% share in 2026 because treatment preparation and administration are closely linked to hospital or specialist workflows.
• Retail Pharmacies includes Chain Pharmacies and Independent Pharmacies. These channels can support prescribed medicines and related care, although intravesical therapies still require an appropriate clinical setting.
• Specialty Pharmacies includes Oncology Pharmacies and Biologic Drug Providers. Their role increases when products need cold-chain, patient-support or reimbursement coordination.
• Others includes Government Procurement and Online Pharmacies. The defined taxonomy captures institutional purchasing and remote ordering routes, subject to the administration and storage requirements of each therapy.

Why does Immunotherapy lead demand within the therapy class category?

Immunotherapy leads because BCG remains an established treatment foundation and recent approvals are adding checkpoint or immune-stimulating mechanisms. The FDA approved durvalumab with BCG for BCG-naive high-risk NMIBC in 2026, while Pfizer's CREST disclosure reported Phase 3 event-free survival results for sasanlimab with BCG.

• Immunotherapy represents 41.0% of therapy-class demand in 2026, supported by BCG-based care and newer immune-oncology combinations.
• Chemotherapy includes Intravesical Chemotherapy and Systemic Chemotherapy. The former includes mitomycin and gemcitabine delivery into the bladder, while systemic chemotherapy is used in selected broader urothelial cancer pathways.
• Targeted Therapy includes FGFR Inhibitors and Antibody-Based Therapy. These categories are retained for therapies directed at defined molecular or antigen-linked mechanisms as the taxonomy expands beyond standard intravesical care.
• Others includes Gene Therapy and Oncolytic Viral Therapy. Ferring's Adstiladrin and CG Oncology's cretostimogene program illustrate how local gene-based and oncolytic approaches add breadth to the development landscape.

What are the drivers, restraints and opportunities in the Non-Muscle Invasive Bladder Cancer Market?

• Driver: High recurrence risk and guideline-backed surveillance keep treatment, follow-up and re-treatment pathways active across Ta, T1 and CIS disease.
• Restraint: BCG-unresponsive disease, progression risk, repeat procedures and the need to avoid delaying cystectomy complicate treatment selection and commercial uptake.
• Opportunity: Sustained local delivery, gene-based therapy, oncolytic immunotherapy and earlier immunotherapy-plus-BCG regimens can widen bladder-preserving options.

Recurrence is the primary demand driver. The NCI treatment guidance notes that stage 0 and I disease often returns after surgery and therefore commonly receives intravesical therapy followed by surveillance. That recurring cycle supports demand for medicines, cystoscopy, resection, pathology and specialist care.

The main restraint is the clinical and operational gap between recurrence control and progression prevention. The FDA label for Anktiva warns that delaying cystectomy in persistent CIS can allow progression to muscle-invasive or metastatic disease. This creates a narrow decision window in which response durability, staging accuracy, patient preference and surgical readiness must be considered together.

The opportunity is to make bladder-preserving treatment more durable and less procedure-intensive. Johnson & Johnson's INLEXZO approval adds extended intravesical gemcitabine delivery for a BCG-unresponsive population, while CG Oncology's 2026 update describes Phase 3 and Phase 2 programs spanning high-risk, BCG-unresponsive, BCG-naive and intermediate-risk NMIBC. These approaches can expand the addressable treatment set if clinical durability, administration and reimbursement align.

Which country CAGRs are profiled in the Non-Muscle Invasive Bladder Cancer Market?

Country	CAGR
USA	8.1%
Japan	7.0%
Germany	7.4%
UK	7.6%
Canada	7.8%
Australia	7.5%
South Korea	8.6%

How do country-level CAGRs compare in the Non-Muscle Invasive Bladder Cancer Market?

The country comparison spans 1.6 percentage points across the approved forecast set, with South Korea at the high end and Japan at the low end. The global market CAGR is 7.7%, so country performance varies around the approved market forecast rather than following a uniform path.

• South Korea leads the profiled countries with an 8.6% CAGR, 0.9 percentage points above the global market CAGR.
• The USA is projected to grow at 8.1%, 0.4 percentage points above the global average.
• Canada is forecast to expand at 7.8%, marginally above the global market CAGR of 7.7%.
• The UK is projected to grow at 7.6%, slightly below the global market average.
• Australia is forecast to record a 7.5% CAGR, followed closely by Germany at 7.4%.
• Japan posts the lowest profiled CAGR at 7.0%, 0.7 percentage points below the global market rate.

Country-wise Analysis

• USA: FDA approvals across BCG-unresponsive, recurrent low-grade and BCG-naive high-risk NMIBC are widening the available treatment pathway. The approved options include systemic immunotherapy, immune-stimulating therapy and sustained intravesical drug delivery.
• Japan: Japan’s public clinical-trial registry includes multinational studies of treatments for intermediate-risk NMIBC, while the Japanese Urological Association recommends risk-based use of TURBT, intravesical chemotherapy and BCG. This supports continued demand for specialist treatment and surveillance capacity.
• Germany: Germany follows the European Association of Urology framework for Ta, T1 and carcinoma in situ, with treatment decisions based on recurrence and progression risk. Updated guidance reinforces demand for accurate staging, intravesical treatment and structured follow-up.
• UK: NICE recommends risk-based intravesical treatment and scheduled cystoscopic follow-up for patients with NMIBC. The recurring surveillance pathway sustains demand for urology services, diagnostic procedures and hospital-administered therapies.
• Canada: Canada’s 2026 Meds Pipeline Monitor identifies late-stage NMIBC programs, including intravesical delivery systems for patients whose disease returns after BCG. The pipeline indicates future demand for regulatory assessment, reimbursement review and specialist administration.
• Australia: The Therapeutic Goods Administration includes pembrolizumab for patients with BCG-unresponsive, high-risk NMIBC with carcinoma in situ who cannot undergo or decline cystectomy. This provides a regulated bladder-preserving option within Australia’s specialist cancer-care pathway.
• South Korea: The Ministry of Food and Drug Safety has published advanced-biopharmaceutical monitoring information covering nadofaragene firadenovec for high-risk BCG-unresponsive NMIBC. This points to growing regulatory preparedness for gene-based bladder therapies and their long-term safety monitoring.

Who are the notable companies in the Non-Muscle Invasive Bladder Cancer Market?

Merck & Co., Inc., Johnson & Johnson, Pfizer Inc., Ferring Pharmaceuticals, CG Oncology, Bristol Myers Squibb, UroGen Pharma Ltd., AstraZeneca PLC, Roche Holding AG and Sesen Bio are the notable companies.

• Merck & Co., Inc. and AstraZeneca PLC: both have FDA-recognized immunotherapy pathways in NMIBC, with pembrolizumab addressing BCG-unresponsive high-risk disease and durvalumab plus BCG addressing BCG-naive high-risk disease.
• Johnson & Johnson, Ferring Pharmaceuticals and UroGen Pharma Ltd.: represent local-delivery platforms through the FDA-approved Inlexzo, Adstiladrin and Zusduri programs.
• Pfizer Inc. and CG Oncology: are advancing late-stage clinical programs that test immune-oncology combinations or intravesical oncolytic immunotherapy across risk and response groups.
• Bristol Myers Squibb and Roche Holding AG: bring checkpoint-inhibitor and bladder-cancer development experience with disclosed NMIBC trial activity or historical evidence.
• Sesen Bio: is a historical entry linked to the Vicineum program; its USA development was paused in 2022 and the company later merged with Carisma Therapeutics, so it should not be read as a current independent NMIBC supplier.

Competitive Benchmarking: Non-Muscle Invasive Bladder Cancer Market

Scoring basis: NMIBC-specific evidence is High for an established product or a disclosed Phase 3 NMIBC program, Medium for a verified clinical-trial or historical NMIBC program, and Low for historical evidence without current development. Local or intravesical delivery is High for a product or program administered into the bladder, Medium for a BCG combination with systemic therapy, and Low for systemic or adjacent evidence. Clinical maturity is High for an established product, Medium for Phase 2 or a late clinical history, and Low where the evidence is historical or the company has no current exact-market program. Coverage evidence records the public label, trial geography or historical program footprint and does not convert missing evidence into a performance rating.

Company	NMIBC-specific evidence	Local / intravesical delivery	Clinical maturity	Coverage evidence
Merck & Co., Inc.	High - KEYTRUDA NMIBC indication	Low - systemic checkpoint	High - FDA approved	USA label; global oncology platform
Johnson & Johnson	High - INLEXZO / TAR-200	High - intravesical gemcitabine system	High - FDA 2025	USA label; multinational clinical program
Pfizer Inc.	High - Phase 3 CREST	Medium - BCG plus subcutaneous PD-1	High - Phase 3	Multinational CREST trial
Ferring Pharmaceuticals	High - ADSTILADRIN	High - intravesical gene therapy	High - FDA approved; Japan NDA	USA and Japan disclosures
CG Oncology	High - BOND-003 and PIVOT-006	High - intravesical oncolytic	High - Phase 3; BLA planned	Multinational trials and access program
Bristol Myers Squibb	Medium - nivolumab NMIBC trials	Low - systemic checkpoint	Medium - clinical-trial history	Multinational oncology development
UroGen Pharma Ltd.	High - ZUSDURI	High - intravesical RTGel	High - FDA 2025	USA label; multinational ENVISION
AstraZeneca PLC	High - IMFINZI plus BCG	Medium - systemic PD-L1 plus intravesical BCG	High - FDA 2026	USA label; global oncology platform
Roche Holding AG	Medium - atezolizumab NMIBC trials	Low - systemic checkpoint	Low - trial history; no current approved NMIBC label	Global oncology; trial history
Sesen Bio	Low - historical Vicineum	High - historical intravesical program	Low - USA program paused; merged 2023	Historical USA program

Key Developments in the Non-Muscle Invasive Bladder Cancer Market

• In May 2026, the FDA approved AstraZeneca PLC's durvalumab with BCG for BCG-naive, high-risk NMIBC.
• In September 2025, the FDA approved Johnson & Johnson's INLEXZO gemcitabine intravesical system for BCG-unresponsive NMIBC.
• In June 2025, the FDA approved UroGen Pharma Ltd.'s ZUSDURI for recurrent low-grade intermediate-risk NMIBC.

Key Players in the Non-Muscle Invasive Bladder Cancer Market

Integrated Immuno-Oncology Platforms

• Merck & Co., Inc.
• Pfizer Inc.
• Bristol Myers Squibb
• AstraZeneca PLC
• Roche Holding AG

Intravesical Drug and Gene Therapy Specialists

• Johnson & Johnson
• Ferring Pharmaceuticals
• UroGen Pharma Ltd.

Bladder-Focused and Historical Local Programs

• CG Oncology
• Sesen Bio

Non-Muscle Invasive Bladder Cancer Market - Report Scope

Coverage field	Report scope
Market breakdown	By treatment type, disease stage, end user, distribution channel, therapy class and region.
Quantitative Units	USD Billion.
Market Definition	The market covers non-muscle invasive bladder cancer treatment pathways across procedures, therapies, delivery channels, end users and regional supply routes.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific and Middle East and Africa.
Countries Covered	USA, Japan, Germany, UK, Canada, Australia and South Korea.
Key Companies Profiled	Merck & Co., Inc., Johnson & Johnson, Pfizer Inc., Ferring Pharmaceuticals, CG Oncology, Bristol Myers Squibb, UroGen Pharma Ltd., AstraZeneca PLC, Roche Holding AG and Sesen Bio
Forecast Period	2026-2036.
Approach	Primary and secondary research with market triangulation.

Non-Muscle Invasive Bladder Cancer Market - Research Methodology

Method	Approach
Primary Research	Analysts examined pharmaceutical developers, urology practices, hospitals, specialty cancer centers, pharmacies, surgical providers and subject-matter experts on risk classification, treatment selection, local administration, follow-up and adoption barriers.
Desk Research	The team reviewed official guidelines, regulatory labels, company releases, trial registries, regulatory sources, peer-reviewed literature and relevant market disclosures.
Market Sizing and Forecasting	Models combined the defined treatment type, disease stage, end-user, distribution-channel, therapy-class and country indicators across the 2026-2036 forecast period.
Data Validation	Findings were checked through source comparison, data triangulation and expert review across regional operating conditions.

Non-Muscle Invasive Bladder Cancer Market by Segments

Non-Muscle Invasive Bladder Cancer Market segmented by Treatment Type:

• Intravesical Immunotherapy
  • BCG Therapy
  • Novel Immunotherapies
• Intravesical Chemotherapy
  • Mitomycin C
  • Gemcitabine
• Surgical Treatment
  • Transurethral Resection of Bladder Tumor (TURBT)
  • Re-TURBT
• Others
  • Targeted Therapy
  • Combination Therapy

Non-Muscle Invasive Bladder Cancer Market segmented by Disease Stage:

• Ta Stage
  • Low-Grade Ta
  • High-Grade Ta
• T1 Stage
  • Primary T1
  • Recurrent T1
• Carcinoma in Situ (CIS)
  • Primary CIS
  • Concurrent CIS

Non-Muscle Invasive Bladder Cancer Market segmented by End User:

• Hospitals
  • Cancer Hospitals
  • General Hospitals
• Specialty Cancer Centers
  • Urology Clinics
  • Oncology Centers
• Ambulatory Surgical Centers
  • Outpatient Surgery Centers
  • Day Care Centers
• Others
  • Research Institutes
  • Academic Medical Centers

Non-Muscle Invasive Bladder Cancer Market segmented by Distribution Channel:

• Hospital Pharmacies
  • Inpatient Pharmacies
  • Outpatient Pharmacies
• Retail Pharmacies
  • Chain Pharmacies
  • Independent Pharmacies
• Specialty Pharmacies
  • Oncology Pharmacies
  • Biologic Drug Providers
• Others
  • Government Procurement
  • Online Pharmacies

Non-Muscle Invasive Bladder Cancer Market segmented by Therapy Class:

• Immunotherapy
  • BCG-Based Therapy
  • Checkpoint Inhibitors
• Chemotherapy
  • Intravesical Chemotherapy
  • Systemic Chemotherapy
• Targeted Therapy
  • FGFR Inhibitors
  • Antibody-Based Therapy
• Others
  • Gene Therapy
  • Oncolytic Viral Therapy

Non-Muscle Invasive Bladder Cancer Market by Region:

• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • France
  • Nordics
  • Benelux
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan and Baltic States
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union Countries
  • Rest of Middle East and Africa

Research Sources and Bibliography

• European Association of Urology (2026). Non-muscle-invasive Bladder Cancer - Introduction.
• European Association of Urology (2026). Pathological Staging and Classification Systems.
• National Cancer Institute (2024, September 12). Treatment of Bladder Cancer by Stage.
• USA Food and Drug Administration (2024, April 22). FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer.
• USA Food and Drug Administration (2025, June 12). FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
• USA Food and Drug Administration (2025, September 9). FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer.
• USA Food and Drug Administration (2026, May 28). FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer.
• USA Food and Drug Administration (2024, August 8). BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment.
• Merck & Co., Inc. (2020, January 8). FDA Approves Merck's KEYTRUDA for Patients with BCG-Unresponsive High-Risk NMIBC.
• Johnson & Johnson (2025, September 9). USA FDA approval of INLEXZO (gemcitabine intravesical system).
• Ferring Pharmaceuticals (2025, April 21). Initial Data from Phase 3 Trial in Japanese Patients with Nadofaragene Firadenovec.
• Ferring Japan (2025, September 11). PMDA Acceptance of NDA Filing for Nadofaragene Firadenovec.
• Pfizer Inc. (2025, April 26). Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk NMIBC.
• CG Oncology (2026, February 27). 2025 Year End Financial Results and Business Updates.
• UroGen Pharma Ltd. (2025, June 12). FDA Approves ZUSDURI (mitomycin) for Recurrent Low-Grade Intermediate-Risk NMIBC.
• Bristol Myers Squibb and ClinicalTrials.gov (n.d.). NCT04149574: Nivolumab and Bacterial Drugs in High-Risk Bladder Cancer.
• Roche (n.d.). Safety and Pharmacology Study of Atezolizumab Alone and in Combination with BCG in High-Risk NMIBC.
• Sesen Bio and USA Securities and Exchange Commission (2022, December 31). Sesen Bio Annual Report and Vicineum Development Update.
• National Institute for Health and Care Excellence (2015, February 25). Bladder cancer: diagnosis and management.
• Patented Medicine Prices Review Board, Government of Canada (2026, April 27). Meds Pipeline Monitor 2026.
• Therapeutic Goods Administration (2023, June 8). AusPAR: Keytruda.
• Ministry of Food and Drug Safety (2025, August 21). Advanced Biopharmaceutical Long-Term Follow-up Information.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the Non-Muscle Invasive Bladder Cancer Market in 2026 and 2036?
• Which treatment type holds the leading share in 2026?
• How does disease stage shape treatment demand?
• Why do hospitals and hospital pharmacies anchor the market?
• Which therapy class leads the defined market taxonomy?
• How do country CAGRs compare across the approved forecast set?
• Which companies serve the Non-Muscle Invasive Bladder Cancer Market?
• What currently drives non-muscle invasive bladder cancer market adoption?
• What limits non-muscle invasive bladder cancer market adoption?
• How should decision-makers compare immunotherapy, chemotherapy, surgery, gene therapy and oncolytic approaches?